BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is reporting third quarter financial results on Thursday 5th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, BCRX is expected to report 3Q20 loss of $ 0.25 per share from revenue of $ 3.60 million.
For the full year, analysts anticipate top line of $ 31.88 million, while looking forward to loss of $ 0.93 per share bottom line.
Previous Quarter Performance
BioCryst Pharmaceuticals, Inc. recorded loss for the second quarter of $ 0.24 per share, from the revenue of $ 2.87 million. The quarterly revenues escalated 97.93 percent compared with the same quarter last year. According to street consensus, BCRX was expected to report 2Q20 loss of $ 0.25 per share from revenue of $ 2.26 million. The bottom line results beat street analysts by $ 0.01 or 4.00 percent, at the same time, top line results outshined analysts by $ 0.61 million or 26.99 percent.
Stock Performance
Shares of BioCryst Pharmaceuticals, Inc. traded up $ 0.32 or 8.10 percent on Wednesday, reaching $ 4.27 with volume of 5.80 million shares. BioCryst Pharmaceuticals, Inc. has traded high as $ 4.30 and has cracked $ 3.88 on the downward trend
The closing price of $ 4.27, representing a 186.23 % increase from the 52 week low of $ 1.38 and a 37.2 % decrease over the 52 week high of $ 6.29.
The company has a market capital of $ 753.94 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
BioCryst Pharmaceuticals, Inc. will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.biocryst.com
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika.
